We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+4.3%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$192M
AUM Growth
+$59.6M
Cap. Flow
+$64.9M
Cap. Flow %
33.84%
Top 10 Hldgs %
51.67%
Holding
90
New
22
Increased
13
Reduced
5
Closed
18

Top Buys

Rank Stock Value
1
ALIM
Alimera Sciences
ALIM
+$9.7M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$7.39M
3
SGMT icon
Sagimet Biosciences
SGMT
+$6.43M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$6.39M
5
BHVN icon
Biohaven
BHVN
+$5.97M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$11.7M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$4.23M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.57M
4
GRI
GRI Bio
GRI
+$1.7M
5
HRMY icon
Harmony Biosciences
HRMY
+$1.14M

Sector Composition

Rank Sector Weight
1 Healthcare 88.02%
2 Consumer Staples 0.32%
3 Communication Services 0.27%
4 Materials 0.15%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KOD icon
76
Kodiak Sciences
KOD
$2.84B
– –
-150,000
Closed -$1.03M
MRSN
77
CALL
DELISTED
Mersana Therapeutics
MRSN
– –
-8,004
Closed -$658K
PSQH icon
78
PSQ Holdings
PSQH
$14.7M
– –
-3,333
Closed -$514K
PSQH.WS icon
79
PSQ Holdings, Inc. Warrants, Each whole warrant exercisable for 1/15th of a share of Class A common stock at an exercise price of $172.50 per share
PSQH.WS
$1.73M
– –
-16,666
Closed -$12.8K
CYCU
80
Cycurion Inc
CYCU
$7.01M
– –
-3,360
Closed -$1.04M
PEPL
81
DELISTED
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
– –
-100,000
Closed -$1.04M
POL
82
DELISTED
Polished.com Inc.
POL
– –
-11,521
Closed -$265K
OHAA
83
DELISTED
OPY Acquisition Corp. I Class A Common Stock
OHAA
– –
-50,000
Closed -$512K
ICPT
84
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-323,000
Closed -$3.57M
RETA
85
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-41,485
Closed -$4.23M
ZEV.WS
86
DELISTED
Lightning eMotors, Inc. Redeemable Warrants, each whole warrant exercisable 1/20th of a share of common stock at an exercise price of $230.00 per whole share
ZEV.WS
– –
-32,608
Closed -$991
POL.WS
87
DELISTED
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
– –
-6,103,824
Closed -$396K
KDNY
88
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-305,000
Closed -$11.7M
MRAI
89
DELISTED
Marpai, Inc. Class A Common Stock
MRAI
– –
-117,848
Closed -$202K
RACYW
90
DELISTED
Relativity Acquisition Corp. Warrant
RACYW
$0 ﹤0.01%
100,000
– –
1 2 3
4

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Altium Capital Management held 90 positions worth $192M, up 45% from $132M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Altium Capital Management deployed $64.9M of net new capital in Q3 2023, opening 22 new positions and adding to 13 existing holdings. Its largest new stake was Alimera Sciences: 2,934,108 shares worth $9.1M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 92% a quarter earlier, followed by Consumer Staples and Communication Services.

On the sell side, the largest reduction was GRI Bio, an estimated $1.7M trimmed.

  • Altium Capital Management's largest Q3 2023 buy was Alimera Sciences: 2,934,108 shares worth $9.1M.
  • Altium Capital Management added most to Amylyx Pharmaceuticals in Q3 2023, an estimated $7.39M increase.
  • Altium Capital Management's biggest Q3 2023 reduction was GRI Bio, cutting an estimated $1.7M.
  • Altium Capital Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $11.7M.
  • Altium Capital Management's ten largest holdings make up 52% of its $192M portfolio in Q3 2023.
  • Altium Capital Management opened 22 new positions and closed 18 in Q3 2023.
  • Altium Capital Management's portfolio value rose 45% quarter-over-quarter to $192M.

Based on Altium Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.